Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EBV TCR-T cell therapy
- Development stage
- Unknown
- Lead developer
- The Affiliated Hospital of Xuzhou Medical University
- Modality
- TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
EBV TCR-T cell therapy is an autologous T-cell receptor (TCR) engineered T-cell therapy designed to target Epstein-Barr virus (EBV) antigens in patients with EBV-associated malignancies. The therapy involves the genetic modification of a patient's T cells to express a TCR specific for the EBV latent membrane protein 2A (LMP2A), restricted by specific human leukocyte antigen (HLA) alleles such as HLA-A*0201, HLA-A*2402, or HLA-A*1101. Developed by the Affiliated Hospital of Xuzhou Medical University, this cell therapy is being evaluated in clinical trials for the treatment of relapsed or refractory EBV-positive lymphomas and nasopharyngeal lymphomas. The mechanism involves the recognition of LMP2A peptides on the surface of tumor cells, leading to T-cell activation and targeted cytotoxicity against the EBV-driven cancer cells.
- Other names
- EBV-specific TCR-engineered T cellsEBV-specific TCR-T cellsEBV-specific TCR-T cell therapy
02
Targets
Epstein–Barr virus latent membrane protein 2A-derived peptide epitopes presented on HLA class I
Beyond the preview
Go deeper on EBV TCR-T cell therapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EBV TCR-T cell therapy.